共 74 条
[1]
Matcham F(2014)The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis Semin Arthritis Rheum 44 123-130
[2]
Scott IC(2011)Co-morbidities in established rheumatoid arthritis Best Pract Res Clin Rheumatol 25 469-483
[3]
Rayner L(2016)Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA Z Rheumatol 75 90-6
[4]
Gullick NJ(2017)Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort Ann Rheum Dis 76 1797-1802
[5]
Scott DL(2021)Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020 Ann Rheum Dis 80 997-1003
[6]
Albrecht K(2017)Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry Arthritis Res Ther 19 253-64
[7]
Callhoff J(2022)A bridge too far? Real-world practice patterns of early glucocorticoid use in the Canadian Early Arthritis Cohort ACR Open Rheumatol 4 57-2556
[8]
Edelmann E(2018)Glucocorticoid-Induced Osteoporosis N Engl J Med 379 2547-R151
[9]
Roubille C(2015)Management of endocrine disease: Secondary osteoporosis: pathophysiology and management Eur J Endocrinol 173 R131-722
[10]
Rincheval N(2002)Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology Ann Rheum Dis 61 718-808